CLDX Key Statistics, Chart & Performance
The current stock price of CLDX is 27.16 USD. In the past month the price increased by 1.84%. In the past year, price increased by 1.31%.
CLDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About CLDX
Company Profile
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. The company is headquartered in Hampton, New Jersey and currently employs 186 full-time employees. The firm is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Company Info
CELLDEX THERAPEUTICS INC
53 Frontage Road, Suite 220
Hampton NEW JERSEY 08827 US
CEO: Anthony S. Marucci
Employees: 186
Phone: 19084547120
CELLDEX THERAPEUTICS INC / CLDX FAQ
Can you describe the business of CELLDEX THERAPEUTICS INC?
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. The company is headquartered in Hampton, New Jersey and currently employs 186 full-time employees. The firm is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Can you provide the latest stock price for CELLDEX THERAPEUTICS INC?
The current stock price of CLDX is 27.16 USD. The price increased by 2.76% in the last trading session.
Does CLDX stock pay dividends?
CLDX does not pay a dividend.
What is the ChartMill technical and fundamental rating of CLDX stock?
CLDX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What sector and industry does CELLDEX THERAPEUTICS INC belong to?
CELLDEX THERAPEUTICS INC (CLDX) operates in the Health Care sector and the Biotechnology industry.
Should I buy CLDX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CLDX.
What is the next earnings date for CLDX stock?
CELLDEX THERAPEUTICS INC (CLDX) will report earnings on 2026-02-25, after the market close.
CLDX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CLDX. When comparing the yearly performance of all stocks, CLDX turns out to be only a medium performer in the overall market: it outperformed 53.69% of all stocks.
CLDX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CLDX. No worries on liquidiy or solvency for CLDX as it has an excellent financial health rating, but there are worries on the profitability.
CLDX Financial Highlights
Over the last trailing twelve months CLDX reported a non-GAAP Earnings per Share(EPS) of -3.38. The EPS decreased by -31.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.63% | ||
| ROE | -37.52% | ||
| Debt/Equity | 0 |
CLDX Forecast & Estimates
22 analysts have analysed CLDX and the average price target is 54.42 USD. This implies a price increase of 100.38% is expected in the next year compared to the current price of 27.16.
For the next year, analysts expect an EPS growth of -52.04% and a revenue growth -58.63% for CLDX